[{"id":"6f307756-0908-4621-b9f3-65923112cc09","acronym":"SHINE ","url":"https://clinicaltrials.gov/study/NCT01776840","created_at":"2021-01-18T07:50:07.776Z","updated_at":"2024-07-02T16:34:37.245Z","phase":"Phase 3","brief_title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01776840 - SHINE ","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-07"},{"id":"d2401e9e-4fcb-4143-a93d-a94dce3674a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939272","created_at":"2021-06-25T22:54:05.033Z","updated_at":"2024-07-02T16:34:58.910Z","phase":"Phase 1/2","brief_title":"Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04939272","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • PAX5 overexpression","tags":["BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • PAX5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 11/23/2024","study_completion_date":" 11/23/2024","last_update_posted":"2024-06-04"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"b7e05237-c123-498d-b356-0eff2ae8d36b","acronym":"ACE-LY-308","url":"https://clinicaltrials.gov/study/NCT02972840","created_at":"2021-01-18T14:36:50.624Z","updated_at":"2024-07-02T16:35:15.640Z","phase":"Phase 3","brief_title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","source_id_and_acronym":"NCT02972840 - ACE-LY-308","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 635","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2025","study_completion_date":" 10/28/2025","last_update_posted":"2024-03-08"},{"id":"7d14cf62-7e9e-43f3-a094-c89f0b0ebda6","acronym":"TrAVeRse","url":"https://clinicaltrials.gov/study/NCT05951959","created_at":"2023-07-20T14:08:45.930Z","updated_at":"2024-07-02T16:35:16.071Z","phase":"Phase 2","brief_title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","source_id_and_acronym":"NCT05951959 - TrAVeRse","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 01/17/2029","primary_completion_date":" 01/17/2029","study_txt":" Completion: 01/17/2029","study_completion_date":" 01/17/2029","last_update_posted":"2024-03-06"},{"id":"6546a747-5131-4b17-8359-960be592eb0d","acronym":"SYMPATICO","url":"https://clinicaltrials.gov/study/NCT03112174","created_at":"2021-01-18T15:20:01.070Z","updated_at":"2024-07-02T16:35:35.516Z","phase":"Phase 3","brief_title":"Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)","source_id_and_acronym":"NCT03112174 - SYMPATICO","lead_sponsor":"Pharmacyclics LLC.","biomarkers":" TP53 • CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • CCND1 overexpression • PAX5 overexpression","tags":["TP53 • CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • CCND1 overexpression • PAX5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2023-09-27"},{"id":"79e6536b-19ce-4949-9d3e-880c5f759980","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932331","created_at":"2021-01-18T19:22:10.688Z","updated_at":"2024-07-02T16:35:53.535Z","phase":"Phase 1/2","brief_title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","source_id_and_acronym":"NCT03932331","lead_sponsor":"AstraZeneca","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 04/29/2020","start_date":" 04/29/2020","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/29/2023","study_completion_date":" 12/29/2023","last_update_posted":"2023-03-10"},{"id":"9499fe25-b413-4c29-a184-18efaa3b0403","acronym":"","url":"https://clinicaltrials.gov/study/NCT02169180","created_at":"2021-01-18T10:06:29.443Z","updated_at":"2024-07-02T16:37:26.297Z","phase":"Phase 2","brief_title":"Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT02169180","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" CD20 • CCND1 • PAX5","pipe":" | ","alterations":" CCND1 expression","tags":["CD20 • CCND1 • PAX5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-24"}]